Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study

NCT07133659

Status	RECRUITING
Phase	Phase 4
Sponsor	Al-Mustansiriyah University
Enrollment	25 participants

Key Eligibility Criteria

Inclusion (4)

- Male or female aged e18 years.
- Diagnosis of primary ITP and having a platelet count of \< 30 x109/L measured within two weeks prior to inclusion with failure to achieve response or relapse after at least one cycle of dexamethasone (20-40 mg daily for 4 days) or prednisone /prednisolone (1 mg/kg for at least two weeks). Shorter courses or lower doses are allowed if discontinued or modified due to side effects.
- Clinical need for second (subsequent) line treatment with a platelet elevating therapy assessed by the physician in charge.
- Signed and dated written informed consent.

Exclusion (15)

- Previous treatment with TPO-RA.
- Pregnancy or lactation.
- Patients with active serious bleeding or at high risk of bleeding as judged by physician in charge.
- Females of child-bearing potential refusing to follow effective contraceptive methods (as described in SmPC) during treatment with Avatrombopag.
- Secondary ITP defined as ITP secondary to lymphoma or chronic lymphocytic leukemia; ITP secondary to the following autoimmune disorders Systemic Lupus Erythematosus or Antiphospholipid Syndrome; ITP secondary to Common Variable Immune Deficiency; ITP secondary to the following viral infections eg Human Immunodeficiency Virus.

... and 10 more (see full listing online)

Locations (1 total)

hematology center / Medical City, Baghdad, Iraq